Grifols SA Operating Income Over Time
| GRFS Stock | USD 9.19 0.35 3.67% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Grifols SA Performance and Grifols SA Correlation. Is there potential for Biotechnology market expansion? Will Grifols introduce new products? Factors like these will boost the valuation of Grifols SA. Market participants price Grifols higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Grifols SA listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 7.5 | Earnings Share 0.63 | Revenue Per Share | Quarterly Revenue Growth 0.04 | Return On Assets |
Investors evaluate Grifols SA ADR using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Grifols SA's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Grifols SA's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Grifols SA's value and its price as these two are different measures arrived at by different means. Investors typically determine if Grifols SA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Grifols SA's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Operating Income Analysis
Compare Grifols SA ADR and related stocks such as Henry Schein, Halozyme Therapeutics, and Molina Healthcare Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HSIC | (9.5 M) | 582.1 M | 634.2 M | 677.1 M | 715.1 M | 768.9 M | 817.5 M | 864.7 M | 693.5 M | 733 M | 567.4 M | 854.8 M | 938 M | 714 M | 729 M | 838.4 M | 493.6 M |
| HALO | (39.7 K) | (19.8 M) | (53.6 M) | (80.4 M) | (63 M) | (27.5 M) | (83.2 M) | 81 M | (69.3 M) | (67.6 M) | 144.3 M | 275.9 M | 267.5 M | 337.6 M | 551.5 M | 634.2 M | 665.9 M |
| MOH | 17.5 M | 80.2 M | 41.1 M | 136.6 M | 192.9 M | 387 M | 306 M | (555 M) | 1.1 B | 1 B | 1.1 B | 1 B | 1.2 B | 1.6 B | 1.7 B | 2 B | 2.1 B |
| ATR | 35.9 M | 287 M | 258.9 M | 284.6 M | 306.4 M | 324.1 M | 310.5 M | 321.5 M | 286.3 M | 371.7 M | 339.5 M | 347.3 M | 379.3 M | 404 M | 496.5 M | 571 M | 599.5 M |
| GMED | 81.9 M | 97.4 M | 114.8 M | 101.7 M | 138.4 M | 172.2 M | 154.1 M | 161.8 M | 169.3 M | 172 M | 111.4 M | 172 M | 228 M | 133.1 M | 166 M | 190.9 M | 155.5 M |
| DVA | 17.2 M | 1.2 B | 1.3 B | 1.6 B | 1.8 B | 1.1 B | 2 B | 1.8 B | 1.5 B | 1.6 B | 1.7 B | 1.8 B | 1.3 B | 1.6 B | 2.1 B | 2 B | 1.1 B |
| BIO | 8.7 M | 295.2 M | 264.1 M | 169.5 M | 150 M | 166.7 M | 53.2 M | 116.7 M | (108.6 M) | 229.7 M | 421.3 M | 500.3 M | 482.6 M | 337.8 M | 269 M | 309.4 M | 324.8 M |
| AVTR | 60.3 M | 60.3 M | 60.3 M | 60.3 M | 60.3 M | 60.3 M | 9.9 M | (210.4 M) | 413.5 M | 551.8 M | 706.8 M | 972.2 M | 1.1 B | 696.4 M | 1.1 B | 1.2 B | 1.3 B |
| MASI | (6.9 M) | 86.5 M | 85.2 M | 79.7 M | 103.5 M | 120.2 M | 435.9 M | 183.8 M | 208 M | 221.2 M | 255.8 M | 275.8 M | 210 M | 136.5 M | (266.7 M) | (306.7 M) | (291.4 M) |
| CORT | (8 M) | (32.3 M) | (36.3 M) | (41.5 M) | (27.6 M) | (3.4 M) | 10.2 M | 52.9 M | 89.5 M | 111.6 M | 128.2 M | 124.5 M | 112.6 M | 107.3 M | 137 M | 157.5 M | 165.4 M |
Grifols SA ADR and related stocks such as Henry Schein, Halozyme Therapeutics, and Molina Healthcare Operating Income description
Operating Income is the amount of profit realized from Grifols SA ADR operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Grifols SA ADR is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Grifols SA ADR | GRFS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Avinguda de la |
| Exchange | NASDAQ Exchange |
USD 9.19
Additional Tools for Grifols Stock Analysis
When running Grifols SA's price analysis, check to measure Grifols SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Grifols SA is operating at the current time. Most of Grifols SA's value examination focuses on studying past and present price action to predict the probability of Grifols SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Grifols SA's price. Additionally, you may evaluate how the addition of Grifols SA to your portfolios can decrease your overall portfolio volatility.